Enhanced CAR-T cell therapy using antigen presenting cells
By using antigen presenting cells (APCs) in CAR T cell therapy to enhance the therapeutic efficacy of CAR T cells, the problems of toxicity and poor amplification of CAR T cell therapy are solved, and more effective tumor treatment is achieved.
CN119654155AInactive Publication Date: 2025-03-18CELLEDIT LLC
3 Cites 2 Cited by
Patent Information
- Application Number
- CN202380030664.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-15
- Filing Date
- 2023-03-14
- Publication Date
- 2025-03-18
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Technical Problem
CAR T cell therapy is toxic when treating certain types of cancer, such as unexpected elevated cytokine levels (cytokine release syndrome) and problems with poor amplification of immune cells in the body.
Method used
The therapeutic efficacy of CAR T cells is enhanced by the use of antigen presenting cells (APCs), including administration of CAR-expressing T cells and APCs to the subjects to improve the amplification and therapeutic effect of CAR T cells in vivo.
Benefits of technology
This method is expected to increase the amplification and survival time of CAR T cells in vivo, enhance the therapeutic effect on tumors, and reduce the risk of cytokine toxicity.
✦ Generated by Eureka AI based on patent content.
Abstract
A cancer therapy comprising both a population of genetically engineered T cells expressing chimeric antigen receptors (CARs) and a population of antigen presenting cells (APCs) that enhance the efficacy of the T cells expressing the CARs.
Need to check novelty before this filing date? Find Prior Art